Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.
Braud VM, Biton J, Becht E, Knockaert S, Mansuet-Lupo A, Cosson E, Damotte D, Alifano M, Validire P, Anjuère F, Cremer I, Girard N, Gossot D, Seguin-Givelet A, Dieu-Nosjean MC, Germain C.
Braud VM, et al.
Oncoimmunology. 2018 Jan 29;7(5):e1423184. doi: 10.1080/2162402X.2017.1423184. eCollection 2018.
Oncoimmunology. 2018.
PMID: 29721382
Free PMC article.